Weight isn't a willpower problem. It's a signaling problem. The gut speaks to the brain in a language called incretin — glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) — and in obesity, that signal is muffled. Restore the signal at the receptor, and appetite, satiety, gastric emptying, and insulin response all reset together. That's why GLP-1 receptor agonism isn't a lever. It's the lever — the single highest-leverage intervention point in modern metabolic medicine. But it isn't the only one, and treating it as a monotherapy is how people lose 18% bodyweight, look skeletal, and rebound 12 months later. This chapter is about why the incretin axis works, and what the corpus says about layering on top of it so you don't pay the lean-mass tax.
What incretin signaling actually does
GLP-1 is secreted from L-cells in the distal small intestine and colon in response to nutrient ingestion. It does four things, all of them load-bearing for weight regulation:
- Suppresses appetite at the hypothalamus. GLP-1 crosses the blood-brain barrier at the area postrema — a circumventricular organ with a porous BBB — and acts on POMC/CART neurons in the arcuate nucleus to reduce hunger drive. The same porous-BBB property is why GLP-1 RAs can directly trigger nausea: the area postrema is also the chemosensory trigger zone for emesis. Mechanism is mechanism — the effect you want and the side effect you don't are wired through the same anatomy.
- Slows gastric emptying. Food stays in the stomach longer. Satiety per calorie goes up. This is why "I just can't finish my plate" becomes the dominant subjective effect within 2-4 weeks.
- Stimulates glucose-dependent insulin secretion. The "glucose-dependent" qualifier matters — insulin only spikes when blood glucose is already elevated, which is why GLP-1 RAs as monotherapy carry low hypoglycemia risk (combination with sulfonylureas or insulin changes that picture).
- Suppresses glucagon when glucose is high. Less hepatic glucose output, lower fasting glucose.
In obesity and type 2 diabetes, endogenous incretin response is blunted. Pharmacological agonism — long-acting analogs that resist DPP-4 degradation — restores and amplifies the signal. That's the entire therapeutic logic.
Why dual and triple agonism outperforms
The practitioner corpus and trial literature converge on a clear hierarchy: mono > dual > triple in efficacy, with safety considerations climbing in parallel.
- Mono (GLP-1 alone) — semaglutide, liraglutide, dulaglutide. Reliable 10-15% total bodyweight loss at maxed dose, mediated through integrated effects on metabolic homeostasis, suppression of chronic inflammation, and improved vascular function.
- Dual (GLP-1 + GIP) — tirzepatide. Network meta-analysis of 3,484 patients confirms tirzepatide outperforms other agents in HbA1c control and weight loss. The GIP arm appears to improve insulin sensitivity and adipose tissue handling beyond what GLP-1 alone delivers.
- Triple (GLP-1 + GIP + glucagon) — retatrutide. The glucagon arm adds an energy-expenditure component — increased thermogenesis and hepatic fat mobilization. Retatrutide produces the largest blood pressure reductions in the class (systolic -7.0 mm Hg, 95% CI -10.5 to -3.5). The trade-off: glucagon receptor activation can elevate heart rate, hepatic aminotransferases, and in higher-risk patients potentially exacerbate cardiovascular or hepatic strain. Higher discontinuation rates have been observed at increased doses.
The practitioner framing is consistent: GLP-1 suppresses hunger, GIP improves nutrient partitioning, glucagon burns. Stack them deliberately.
The titration protocol (Phase 1 — Weeks 1-4 reset)
This chapter introduces the incretin backbone. Phase 2 (Weeks 5-10) layers in the muscle-preservation and metabolic-support stack, covered in subsequent chapters.
| Compound | Dose | Route | Frequency | Evidence Tier | Notes |
|---|---|---|---|---|---|
| Semaglutide | 0.25 mg → titrate 0.5 → 1.0 → 1.7 → 2.4 mg over 16+ weeks | Subcutaneous (abdomen, thigh, upper arm) | Weekly | 🔵 Clinical | FDA-approved (Wegovy ≥30 BMI, or ≥27 BMI with comorbidity). Titrate slowly — nausea is dose-dependent. |
| Tirzepatide | 2.5 mg → titrate 5 → 7.5 → 10 → 12.5 → 15 mg, minimum 4 weeks per step | Subcutaneous | Weekly | 🔵 Clinical | Dual GLP-1/GIP. Superior weight loss and HbA1c control vs. semaglutide in head-to-head. |
| Retatrutide | 2 mg → titrate 4 → 8 → 12 mg | Subcutaneous | Weekly | 🟣 Experimental | Triple agonist. Largest weight loss signal in class. Monitor HR, ALT, and BP. Phase 3 ongoing — not yet FDA-approved. |
| AOD-9604 | 250-500 mcg | Subcutaneous (fasted, AM) | Daily, 5 days on / 2 off | 🟢 Expert | Fragment 176-191 of hGH. Lipolytic only — no receptor downregulation, no insulin resistance effect, no hunger increase. Stacks cleanly with GLP-1 without overlap. |
| MOTS-c | 5-10 mg | Subcutaneous | 2-3× weekly | 🟢 Expert | Mitochondrial-derived peptide. Restores insulin sensitivity and glucose utilization via AMPK activation. Substrate-supported for metabolic dysregulation in obesity, PCOS, T2DM. Pairs with the incretin stack to address the mitochondrial side of metabolic syndrome rather than only the appetite side. |
Pick one incretin agonist. Do not stack semaglutide + tirzepatide + retatrutide. Receptor saturation is real; side-effect stacking is worse. The decision tree: semaglutide if you want the most established cardiovascular and renal safety record (SUSTAIN-6, FLOW, SELECT). Tirzepatide if you want maximum weight loss with the best-validated dual-agonist safety profile. Retatrutide if you're an experienced operator, tracking labs aggressively, and accept Experimental-tier risk in exchange for the largest effect size in the class.
AOD-9604 and MOTS-c are additive — they hit lipolysis and mitochondrial function through pathways the incretins don't touch.
What you should feel
- Week 1-2 — Reduced appetite within 48-72 hours of first dose. Earlier satiety per meal. Some nausea, mild GI discomfort. Hunger thoughts quiet down — described in the corpus as "food noise" disappearing.
- Week 3-4 — Plate-finishing becomes hard. Sweet/hyperpalatable cravings drop sharply. Disinhibition scores improve. 2-5 kg loss is common by week 4 at titration doses. Energy may dip — this is partly caloric deficit, partly glucagon-arm thermogenic load (if on retatrutide).
What's NOT happening yet
- You are not preserving lean mass on this stack alone. GLP-1 RA monotherapy is associated with inadvertent and significant loss of lean body mass, including muscle. Phase 2 (Weeks 5-10) introduces the muscle-preservation layer — resistance training prescription, protein floor, and the GH-axis stack (CJC-1295/Ipamorelin, MOTS-c continuation, optionally tesamorelin) — for exactly this reason. Treating Phase 1 as the whole protocol is the single most common failure mode.
- You are not "fixing" metabolism long-term. Weight regain on discontinuation is well-documented. The incretin axis normalizes signal while you're on it. Off-ramp planning starts at Phase 3 (maintenance), not at week 10.
- You are not safe to combine with ketogenic diets without supervision. Euglycemic DKA has been reported with tirzepatide + ketosis-inducing diet combinations. If you're running keto, you need ketone monitoring, not just glucose monitoring.
- You are not getting glucagon-arm benefits from semaglutide. Thermogenic and hepatic-fat-mobilization effects belong to glucagon receptor activity. If liver fat reduction or energy expenditure is a primary goal and you can tolerate the safety profile, retatrutide is the substrate-supported choice — not a higher dose of semaglutide.
- You are not done titrating in 4 weeks. Manufacturer protocols and the practitioner consensus both push minimum 4-week steps. Rushing the titration is how nausea becomes vomiting becomes dehydration becomes discontinuation.
The corpus describes this axis as the highest-leverage single intervention in modern metabolic medicine — track the lean mass, track the labs, and respect the titration.